In Reply We thank Drs Strum and Scholz for their interest and clinical perspective on our recent study. Many of the points they raised were addressed in the discussion section of our article. Our analysis did not focus on quality of life; it focused on long-term outcomes. We noted that in some of the previous trials patients receiving intermittent therapy had improved sexual function, physical activity, and general well-being, but these results often did not persist over time.1 Our analysis focused on long-term health events. We did not find that patients randomly assigned to intermittent androgen deprivation therapy had consistently fewer long-term adverse health events compared with those receiving continuous ADT.
Hershman DL, Unger JM. Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer—Reply. JAMA Oncol. 2016;2(5):686-687. doi:10.1001/jamaoncol.2016.0370